SG11201810308TA - Oral tipepidine preparation - Google Patents
Oral tipepidine preparationInfo
- Publication number
- SG11201810308TA SG11201810308TA SG11201810308TA SG11201810308TA SG11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA SG 11201810308T A SG11201810308T A SG 11201810308TA
- Authority
- SG
- Singapore
- Prior art keywords
- tipepidine
- oral
- preparation
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ORAL TIPEPIDINE PREPARATION In the present invention, the drug dissolution rate of tipepidine or a pharmaceutically acceptable salt thereof is controlled to thereby provide a new oral composition of once- or twice-a-day dosage type comprising tipepidine or a pharmaceutically acceptable salt thereof. FIG. 10
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016107387 | 2016-05-30 | ||
PCT/JP2017/020038 WO2017209106A1 (en) | 2016-05-30 | 2017-05-30 | Oral tipepidine preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810308TA true SG11201810308TA (en) | 2018-12-28 |
Family
ID=60478572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810308TA SG11201810308TA (en) | 2016-05-30 | 2017-05-30 | Oral tipepidine preparation |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP6380922B2 (en) |
KR (1) | KR20180137566A (en) |
PH (1) | PH12018502490A1 (en) |
SG (1) | SG11201810308TA (en) |
TW (1) | TW201803564A (en) |
WO (1) | WO2017209106A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0759521B2 (en) * | 1985-09-30 | 1995-06-28 | 藤沢薬品工業株式会社 | Gel layer-forming sustained-release preparation |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
JPH05255125A (en) * | 1992-02-29 | 1993-10-05 | Upjohn Co:The | Sustained release preparation and its preparation |
JPH1017497A (en) * | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | Sustained release pharmaceutical preparation and its production |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
JP5850299B2 (en) * | 2010-04-28 | 2016-02-03 | 国立大学法人 熊本大学 | Obsessive-compulsive disorder treatment |
JP6032561B2 (en) * | 2011-03-03 | 2016-11-30 | 国立大学法人 熊本大学 | Drugs that improve central function in pain |
JP5858477B2 (en) * | 2011-09-01 | 2016-02-10 | 国立大学法人 熊本大学 | Drugs for negative symptoms of schizophrenia |
CR20190073A (en) * | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | DOSAGE FORMS OF RUXOLITINIB OF SUSTAINED RELEASE (Divisional 2015-265) |
-
2017
- 2017-05-30 JP JP2018518663A patent/JP6380922B2/en not_active Expired - Fee Related
- 2017-05-30 KR KR1020187035519A patent/KR20180137566A/en not_active Application Discontinuation
- 2017-05-30 WO PCT/JP2017/020038 patent/WO2017209106A1/en active Application Filing
- 2017-05-30 SG SG11201810308TA patent/SG11201810308TA/en unknown
- 2017-05-31 TW TW106117949A patent/TW201803564A/en unknown
-
2018
- 2018-11-26 PH PH12018502490A patent/PH12018502490A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201803564A (en) | 2018-02-01 |
PH12018502490A1 (en) | 2019-09-30 |
WO2017209106A1 (en) | 2017-12-07 |
KR20180137566A (en) | 2018-12-27 |
JP6380922B2 (en) | 2018-08-29 |
JPWO2017209106A1 (en) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
EA201792592A1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN | |
MX2020012978A (en) | Pharmaceutically acceptable salts of sepiapterin. | |
EA201992116A1 (en) | PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL | |
EA201792591A1 (en) | PHARMACEUTICAL PREPARATIONS | |
EA201691789A1 (en) | PHARMACEUTICAL COMPOSITIONS AND SALTS OF 1,2,4-OXADIAZOLBENZOIC ACID | |
MX2020007552A (en) | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate. | |
MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
MX2018000084A (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin. | |
MX2016014696A (en) | Combinations of formoterol and budesonide for the treatment of copd. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
EA201892842A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID | |
MX2018014184A (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist. | |
SG11201810308TA (en) | Oral tipepidine preparation | |
EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
PH12017501736A1 (en) | Indole derivatives | |
PH12017500536A1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
PH12016502527B1 (en) | Stabilized desmopressin | |
EA201692426A1 (en) | COMBINATIONS OF ZALTOPROFENA AND MIORELAXANT | |
MX2017014725A (en) | Dropropizine in combination with ambroxol in the dosage form of syrup or tablets. | |
TR201722852A2 (en) | Oral pharmaceutical compositions of mesalazine | |
MX2018007272A (en) | Pulsatile release pharmaceutical composition comprising naftazone or one of its salts. | |
EA201891911A1 (en) | APPLICATION OF TAMOXIFEN FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS OF BOTH FLOORS | |
MX2014008984A (en) | Obtention process and pharmaceutical composition of capsules of fenofibrate as a lipid regulator of oral administration. |